


DTIC FILE COPY



Naval Medical Research Institute

Bethesda, MD 20814-6066

NMRI 88-97

December 1988

MEPACRINE-INDUCED SENSITIZATION OF RATS TO BACTERIAL ENDOTOXIN

AD-A209 643

S. L. Gartner and K. M. M. Shakir

DTIC
S ELECTE **D**
JUN 27 1989
D *CS* **D**

Approved for public release;
distribution is unlimited

Naval Medical Research
and Development Command
Bethesda, Maryland 20814-5044

Department of the Navy
Naval Medical Command
Washington, D.C. 20372-5210

20030131197

89

6 26 044

NOTICES

The opinions and assertions contained herein are the private ones of the writer and are not to be construed as official or reflecting the views of the naval service at large.

When U.S. Government drawings, specifications, or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

Please do not request copies of this report from the Naval Medical Research Institute. Additional copies may be purchased from:

National Technical Information Service
5285 Port Royal Road
Springfield, Virginia 22161

Federal Government agencies and their contractors registered with the Defense Technical Information Center should direct requests for copies of this report to:

Defense Technical Information Center
Cameron Station
Alexandria, Virginia 22304-6145

TECHNICAL REVIEW AND APPROVAL

NMRI 88-97

The experiments reported herein were conducted according to the principles set forth in the current edition of the "Guide for the Care and Use of Laboratory Animals," Institute of Laboratory Animal Resources, National Research Council.

This technical report has been reviewed by the NMRI scientific and public affairs staff and is approved for publication. It is releasable to the National Technical Information Service where it will be available to the general public, including foreign nations.

KURT SORENSEN

CAPT MC USN

Commanding Officer
Naval Medical Research Institute

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE

REPORT DOCUMENTATION PAGE

1a. REPORT SECURITY CLASSIFICATION Unclassified		1b. RESTRICTIVE MARKINGS	
2a. SECURITY CLASSIFICATION AUTHORITY		3. DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release; distribution is unlimited	
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE		4. PERFORMING ORGANIZATION REPORT NUMBER(S) NMRI 88-97	
4. PERFORMING ORGANIZATION REPORT NUMBER(S) NMRI 88-97		5. MONITORING ORGANIZATION REPORT NUMBER(S)	
6a. NAME OF PERFORMING ORGANIZATION Naval Medical Research	6b. OFFICE SYMBOL (if applicable)	7a. NAME OF MONITORING ORGANIZATION Naval Medical Command	
6c. ADDRESS (City, State, and ZIP Code) Bethesda, Maryland 20814-5055		7b. ADDRESS (City, State, and ZIP Code) Department of the Navy Washington, D.C. 20372-5120	
8a. NAME OF FUNDING/SPONSORING ORGANIZATION Naval Medical Research and Development Command	8b. OFFICE SYMBOL (if applicable)	9. PROCURMENT INSTRUMENT IDENTIFICATION NUMBER	
8c. ADDRESS (City, State, and ZIP Code) Bethesda, Maryland 20814-5055		10. SOURCE OF FUNDING NUMBERS	
		PROGRAM ELEMENT NO. 61153N	PROJECT NO. MR04120
		TASK NO. .05-1004	WORK UNIT ACCESSION NO. DN247511
11. TITLE (Include Security Classification) Mepacrine-induced sensitization of rats to bacterial endotoxin			
12. PERSONAL AUTHOR(S) Gartner SL, Shakir KM			
13a. TYPE OF REPORT Technical Report	13b. TIME COVERED FROM _____ TO _____	14. DATE OF REPORT (Year, Month, Day) December 1988	15. PAGE COUNT 13
16. SUPPLEMENTARY NOTATION			
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Endotoxin toxicity Mepacrine Nucleic acid synthesis Rats Splenocytes
FIELD	GROUP	SUB-GROUP	
19. ABSTRACT (Continue on reverse if necessary and identify by block number)			
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> OTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION Unclassified	
22a. NAME OF RESPONSIBLE INDIVIDUAL Phyllis Blum, Information Services Division		22b. TELEPHONE (Include Area Code) 202-295-2188	22c. OFFICE SYMBOL ISD/ADMIN/NMRI

DD FORM 1473, 84 MAR

83 APR edition may be used until exhausted.
All other editions are obsolete.SECURITY CLASSIFICATION OF THIS PAGE
UNCLASSIFIED

ACKNOWLEDGMENTS

The authors wish to express their appreciation to Ms. Julie Crockett and Ms. Debbie Hicks for typing the manuscript and Mr. James Lyles for his technical assistance. We would also like to thank Dr. Louis D. Homer for numerous helpful discussions and the statistical analysis of the data.

The experiments conducted herein were conducted according to the principles set forth in the current edition of the "Guide for the Care and Use of Laboratory Animals," Institute of Laboratory Resources, National Research Council.



Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

Table of Contents

	page
Introduction	1
Results	
Table I, Figure 1	3
Discussion	4
References	6
Figure Legends	8

INTRODUCTION

Investigations in the past several years have implicated prostaglandin release in the pathogenesis of endotoxin shock (4,5). These studies have focused on the observation that prostaglandin levels are increased following endotoxin administration. Furthermore, indomethacin, a compound that inhibits prostaglandin formation (6), has been shown to protect animals from bacterial endotoxin (2). Since another effect of indomethacin is to inhibit phospholipase A₂^M (10, 11), the initial purpose of this study was to determine whether or not other inhibitors of phospholipase A₂^M, such as mepacrine, would also be protective. Information of this nature would be useful in understanding the mechanism of endotoxin toxicity, as well as a possible treatment for sepsis. Thus, we injected rats with endotoxin and mepacrine. Instead of protection, however, we found that mepacrine sensitized the animals to endotoxin. A preliminary account of this work has been presented in abstract form (7). → (AW) X

METHODS

Mepacrine was a gift from the Sterling-Winthrop Research Institute, Rensselaer, New York. *S. enteritidis* endotoxin (Boivin preparation lot #678167) was purchased from Difco Laboratories, Detroit, Michigan. Radiolabelled chemicals; leucine ¹⁴C (56.9 mCi/mmole), thymidine ¹⁴C (47.5 mCi/mmole), and uridine ³H (25.4 Ci/mmole) were obtained from New England Nuclear, Boston, Massachusetts.

Lethality studies were performed on adult, male Sprague-Dawley rats weighing between 180 and 220 grams. Compounds were injected separately in a volume of approximately 0.5 ml while the rats were under ether anesthesia. Various doses of the S. enteritidis endotoxin were dissolved in phosphate buffered saline (PBS) and administered via the femoral vein. Immediately following the endotoxin, animals received intraperitoneal injection of either PBS (control) or mepacrine (50 mg/Kg) dissolved in PBS. Mortality was observed after 72 hours and the data were analyzed for statistical significance by the maximum likelihood method (9).

For the studies on protein and nucleic acid synthesis, spleens were removed from rats and the cells were gently teased from the spleen in minimal essential media containing 25 mM N-2-hydroxyethylpiperazine N-2-ethanesulfonic acid (HEPES) and 1% fetal calf serum. The splenocytes were depleted of red blood cells by treatment with ammonium chloride lysing buffer, washed, and passed through nylon (HC3-110, Tetco, Inc., Elmsford, NY). Splenocytes (approximately 1×10^7 cells/ml) were incubated at 37°C in 3 ml of minimal essential media containing 25 mM HEPES and 1% fetal calf serum. After a 10-minute preincubation period, 10 uCi of radiolabelled leucine, uridine, or thymidine were added to start the reaction. Aliquots (0.5 ml) were removed at timed intervals and incorporation of radioactivity into protein or nucleic acid was measured by precipitation with 0.5 ml of 20% trichloroacetic acid. The precipitates were washed three times dissolved in 1 M KOH and neutralized with 1 N HCl. Radioactivity was determined by liquid scintillation spectrometry using Aquasol-2.

RESULTS

The results in Table 1 show that mepacrine (50 mg/Kg) increased the sensitivity of rats to bacterial endotoxin approximately threefold from 15.9 to 4.6 mg endotoxin/Kg. The dose of mepacrine (50 mg/kg) that was used was not toxic when administered without endotoxin (16 rats). Furthermore, intraperitoneal injection of mepacrine (100 mg/Kg, N=16), followed by intravenous PBS produced no deaths. These experiments clearly show that mepacrine, instead of being protective, actually produced significant sensitization ($p < 0.0001$) to endotoxin.

In addition to the inhibition of phospholipase A₂ activity, mepacrine has other effects that may be responsible for the increased sensitization to bacterial endotoxin. One of the other actions of mepacrine is the inhibition of protein and nucleic acid synthesis (13), and since other agents that inhibit protein and nucleic acid biosynthesis are known to sensitize animals to endotoxin (1), we examined the effect of mepacrine on the ability of rat splenocytes to synthesize protein and nucleic acid. These data in Figure 1 show that 10^{-4} M mepacrine markedly inhibited protein and nucleic acid synthesis: leucine incorporation into protein was reduced to 11% of control; uridine incorporation into RNA was reduced to 1% of control and thymidine incorporation into DNA was reduced to 20% of control in the presence of 10^{-4} M mepacrine. Assuming that 50 mg mepacrine/Kg dose used in the lethality studies were distributed evenly throughout the body of the rat, it would correspond very closely to the 10^{-4} M mepacrine concentration that produced these marked effects on spleen cells in vitro.

TABLE 1. EFFECT OF MEPACRINE ON LEIHALITY OF ENDOTOXIN IN RATS

Treatment	LD ₅₀ (mg/Kg)	Significance
vehicle + endotoxin (70 rats)	15.9	
mepacrine (50 mg/Kg) + endotoxin	4.6	< 0.0001

Rats were given intravenous injection of endotoxin and either vehicle or mepacrine as described in the Methods section. Mortality was observed after 72 hours.

Effect Of Mepacrine On Protein And Nucleic Acid Synthesis In Rat Splenocytes




FIGURE 1

DISCUSSION

Mepacrine (Quinacrine, Atabrine[®]) is an acridine derivative developed in the 1930s for treatment of malaria. Since the development of more effective, less toxic antimalarials, mepacrine is no longer used for this purpose. When taken orally, mepacrine is readily absorbed and accumulates predominantly in liver and spleen. Intracellularly, it is distributed in the nucleus and lysosomal fractions (13). Besides its action as an inhibitor of phospholipase A₂ (14), mepacrine has several other biological activities. These include inhibition of glucose metabolism and nucleic acid synthesis (13), inducer of interferon (8) and inhibition of calmodulin-activated Ca-ATPase and phosphodiesterase (16). Like other acridine dyes, mepacrine forms a tight complex with DNA which effectively blocks DNA-dependent DNA and RNA polymerase reactions (3). This later effect of mepacrine probably explains the marked depression of protein and nucleic acid synthesis that we observed in rat splenocytes. The inhibitory effect of mepacrine on phospholipase A₂ activity has been well documented (14, 15). For example, Vadas' work shows that mepacrine (10⁻⁶ to 10⁻³ M) inhibits phospholipase A₂ in rabbit peritoneal exudate cells (14). However, the data of Chan et al. (2), using rat platelets, suggests there might be a biphasic modulation of phospholipase A₂ activity depending upon the concentration of mepacrine. At low mepacrine concentrations (50 to 100 μM) inhibition of phospholipase A₂ occurs, while at a higher mepacrine concentration (500 μM) there is stimulation of activity (2). This brief description of the diverse effects of mepacrine suggests that this drug could have multiple actions that effect survival after endotoxin administration.

In the present study, we found that a nontoxic dose of mepacrine sensitizes rats approximately threefold to bacterial endotoxin. The mechanism of the increased sensitivity caused by mepacrine cannot be determined from our current data, but the fact that mepacrine did effectively inhibit protein and nucleic acid synthesis and that other agents that inhibit protein and nucleic acid synthesis also sensitize to endotoxin suggests that mepacrine may also be acting in this way. Our data on the mepacrine-endotoxin interaction does illustrate the complexity of using whole animals models, as well as the danger of viewing one action of a drug, such as phospholipase A₂ inhibition, and neglecting side effects that may produce very opposing results.

REFERENCES

1. Bradley, S.C. Alteration of the sensitivity of mice to bacterial endotoxin. In: P. Rosenberg, (Ed.), Toxins: Animal, Plant and Microbial. Proceedings from the Fifth International Symposium, New York: Pergamon Press, 1978, pp. 907-920.
2. Chen, A.C., Pritchard, E.T., Gerrard, J.M., Man, R.Y.K., and Choy, P.C. Biphasic modulation of platelet phospholipase A₂ activity and platelet aggregation by mepacrine (Quinacrine). Biochem. Biophys. Acta, 713:170, 1982.
3. Ciak, J., and Hahn, F.E. Quinacrine (Alebrine): Mode of action. Science, 156:655, 1967.
4. Cook, J.A., Wise, W.C., and Halushka, P.V. Elevated thromboxane levels in the rat during endotoxic shock. J. Clin. Invest. 65:227, 1980.
5. Fletcher, J.R., and Ramwell, P.W. The role of prostaglandin synthesis inhibitors in shock and trauma. In: P.W. Ramwell (Ed.), Prostaglandin synthetase inhibitors: New clinical applications proceedings, New York: Alan R. Liss, 1980, pp. 257-266.
6. Flower, R.J. Drugs which inhibit prostaglandin synthesis. Pharmacol. Rev., 26:33, 1974.
7. Gartner, S.L. and Shakir, K.M.M. Mepacrine sensitization of rats to bacterial endotoxin. Fed. Proc., 41:1134, 1982.
8. Glaz, E.T., and Talas, M. Comparison of the activity of small molecular weight interferon inducers: Tilorone and acridine dyes. Arch. Virology, 48:375, 1975.

9. Homer, L.D., and Bailey, R.C. An analogy permitting maximum likelihood estimation by a simple modification of general least squares algorithms. Naval Medical Research and Development Command Report, Bethesda, Maryland, September 1977.
10. Kaplan, L., Weiss, J., and Elsbach, P. Low concentrations of indomethacin inhibit phospholipase A₂ of rabbit polymorpholeukocytes. Proc. Nat. Acad. Sci., 75:2955, 1978.
11. Shakir, K.M.M., O'Brian, J.T., and Gartner, S.L. Enhanced phospholipase A₂ activity in rat plasma, liver, and intestinal mucosa following endotoxin treatment: A possible explanation for the protective effect of indomethacin in endotoxic shock. Metabolism, in press.
12. Short, B.L., Gardiner, M., Walker, R.I., Jones, S.R., and Fletcher, J.R. Indomethacin improves survival in gram-negative sepsis. Adv. Shock Res. 6:27, 1981.
13. Thompson, P.E., and Werbel, L.M. Acridines: Chemistry and pharmacology, Vol. 12. In: G. de Stevens (Ed.), Anti-malarial agents, New York: Academic Press, pp. 123-147, 1972.
14. Vadas, P. The efficacy of anti-inflammatory agents with respect to extracellular phospholipase A₂ activity. Life Sciences, 30:155, 1982.
15. Vigo, C., Lewis, G.P., and Piper, P. Mechanisms of inhibition of phospholipase A₂. Biochem. Pharmacol., 29:623, 1980.
16. Volpi, M, Sha'afi, R.I., Epstein, P.M., Andrenyak, D., and Feinstein, M.B. Antagonism of calmodulin by local anesthetics, mepacrine and propranolol. Ann. N.Y. Acad. Sci. 356:441, 1980.

FIGURE LEGEND

Figure 1. Protein, RNA, and DNA synthesis were measured by incubating splenocytes with radiolabelled leucine, uridine, or thymidine, and counting the trichloroacetic acid precipitates as described in Methods section. Experiments were performed at least three times and the results shown are that of one experiment with individual assays performed in triplicate. The data are expressed as % of control incorporation + S.D. Statistical analysis was performed using the Student's t test, * $p < 0.011$.